Latest news with #MonarchNetworthCapital
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Stock calls, July 4: Natco Pharma, Sharda Cropchem among top stocks to buy
Stocks to buy: Analyst pick Sharda Cropchem, Monarch Networth Capital and one more share to buy; Check full details Kunal Kamble Mumbai Stock recommendations Sharda Cropchem Sharda Cropchem has given a breakout above its resistance level and closed higher, indicating buyer dominance. The rise in volume during the breakout confirms strong buying interest at current levels. The stock is trading above all major Exponential Moving Averages (EMAs), suggesting a firm positive trend. The RSI, after a brief consolidation, has turned upward, supporting the ongoing price action. Additionally, DI+ trading above DI- signals a bullish stance, while the ADX above both DI lines reflects strength in the upmove. The stock can be accumulated at current levels, with a stop-loss at ₹830 and an upside target of ₹998. Sharda Cropchem: ₹886.90 Stop loss: ₹830 Monarch Networth Capital Monarch Networth has given a breakout from its recent trading range, accompanied by a rise in volume, indicating buyer dominance over sellers. The stock has managed to close above all major EMAs, which suggests the trend remains positive. The RSI is moving higher, supporting the ongoing price action. Additionally, DI+ trading above DI- indicates a bullish bias, while the ADX trading above DI− signals strength in the current upmove. The stock can be accumulated in the range of ₹355–₹372, with a stop-loss at ₹337, for an upside target of ₹391–₹450. Monarch Networth Capital: ₹371.95 Stop Loss: ₹337 Target Price: ₹391/₹450 Natco Pharma Natco Pharma has taken support near the ₹890 level, which previously acted as a strong base from where the stock had rallied up to ₹1,639. Once again, buyers have stepped in at this level, pushing the price higher to ₹973, with the stock now closing above the 9, 21, and 50 EMAs on the weekly timeframe-a sign of emerging bullish momentum. The rise in volume confirms buying interest at current levels. The RSI has crossed above the 50 mark, indicating improving momentum. Additionally, on the weekly chart, DI+ has crossed above DI−, further supporting the positive outlook. The stock can be accumulated on dips toward ₹912, with a stop-loss at ₹840, for an upside target of ₹1,140–₹1,200. Natco Pharma: ₹973.60 Stop Loss: ₹840 Target Price: ₹1140/₹1200
Business Standard
28-05-2025
- Business
- Business Standard
Monarch Networth Capital consolidated net profit declines 19.06% in the March 2025 quarter
Sales decline 10.61% to Rs 60.97 crore Net profit of Monarch Networth Capital declined 19.06% to Rs 24.72 crore in the quarter ended March 2025 as against Rs 30.54 crore during the previous quarter ended March 2024. Sales declined 10.61% to Rs 60.97 crore in the quarter ended March 2025 as against Rs 68.21 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.21% to Rs 149.27 crore in the year ended March 2025 as against Rs 123.15 crore during the previous year ended March 2024. Sales rose 17.69% to Rs 326.80 crore in the year ended March 2025 as against Rs 277.69 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 60.9768.21 -11 326.80277.69 18 OPM % 62.6556.06 - 66.3363.96 - PBDT 36.6240.55 -10 200.28165.88 21 PBT 34.7340.03 -13 192.74164.15 17 NP 24.7230.54 -19 149.27123.15 21
